Recommendations for follow up in castration resistant prostate cancer

被引:0
|
作者
Vazquez-Alonso, Fernando [1 ]
Puche-Sanz, Ignacio [1 ]
Manuel Cozar-Olmo, Jose [1 ]
机构
[1] Hosp Univ Virgen Nieves, UGC Urol, Avda Fuerzas Armadas 2, Granada 18014, Spain
来源
ARCHIVOS ESPANOLES DE UROLOGIA | 2018年 / 71卷 / 08期
关键词
Prostate cancer; Diagnosis; Follow up; Castration resistance; Metastases; CLINICAL-TRIALS; FREE SURVIVAL; PHASE-II; ENZALUTAMIDE; ABIRATERONE; GUIDELINES; DISEASE; DESIGN; PET/CT; MEN;
D O I
暂无
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVES: There is no broad consensus about what diagnostic tests use for CRPC follow up as well as their frequency. Our objective is to review and analyze the most important CRPC follow up patterns described in the literature to date. METHODS: We performed a critical analysis of the recommendations for follow up most universally employed (PCWG3, RADAR, St Gallen consensus, NCCN guidelines, EAU guidelines) RESULTS: CT scan and bone scan are the routine recommended diagnostic tests, in front of other techniques such as PET/CT or MRI, that may improve the diagnostic efficacy but they have the problem of availability and lack of internal validity for follow up. CONCLUSIONS: Follow up is different for non metastatic and metastatic CRPC. For nm CRPC, it is recommended to perform monitoring that includes PSA and imaging tests, without consensus about periodicity. For mCRPC, it is recammendable to do follow up with periodic PSA and imaging tests, since it is possible to have radiological progression without PSA progression.
引用
收藏
页码:735 / 742
页数:8
相关论文
共 50 条
  • [21] Sequencing Treatment for Castration-Resistant Prostate Cancer
    Handy, Catherine E.
    Antonarakis, Emmanuel S.
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2016, 17 (12)
  • [22] PSMA theragnostics for metastatic castration resistant prostate cancer
    Song, Hong
    Guja, Kip E.
    Iagaru, Andrei
    TRANSLATIONAL ONCOLOGY, 2022, 22
  • [23] Olaparib for Metastatic Castration-Resistant Prostate Cancer
    de Bono, J.
    Mateo, J.
    Fizazi, K.
    Saad, F.
    Shore, N.
    Sandhu, S.
    Chi, K. N.
    Sartor, O.
    Agarwal, N.
    Olmos, D.
    Thiery-Vuillemin, A.
    Twardowski, P.
    Mehra, N.
    Goessl, C.
    Kang, J.
    Burgents, J.
    Wu, W.
    Kohlmann, A.
    Adelman, C. A.
    Hussain, M.
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (22) : 2091 - 2102
  • [24] Treatment of metastatic, castration-resistant prostate cancer
    von Amsberg, G.
    Merseburger, A. S.
    UROLOGE, 2020, 59 (06): : 673 - 679
  • [25] Darolutamide for treatment of castration-resistant prostate cancer
    Rhea, L. P.
    Mendez-Marti, S.
    Aragon-Ching, J. B.
    DRUGS OF TODAY, 2020, 56 (03) : 185 - 193
  • [26] Austrian recommendations on Targeted Hormone Therapy for metastatic, castration-resistant prostate cancer
    Ponholzer, Anton
    Loidl, Wolfgang
    Bektic, Jasmin
    Dorfinger, Karl
    Hruby, Stephan
    Jeschke, Klaus
    Kramer, Gero
    Krause, Steffen
    Ludvik, Georg
    Remzi, Mesut
    Roider, Michael
    Stoiber, Franz
    WIENER KLINISCHE WOCHENSCHRIFT, 2016, 128 (3-4) : 156 - 163
  • [27] Abiraterone acetate in castration-resistant prostate cancer
    Iacovelli, Roberto
    Palazzo, Antonella
    Procopio, Giuseppe
    Gazzaniga, Paola
    Cortesi, Enrico
    ANTI-CANCER DRUGS, 2012, 23 (03) : 247 - 254
  • [28] Austrian recommendations on Targeted Hormone Therapy for metastatic, castration-resistant prostate cancer
    Anton Ponholzer
    Wolfgang Loidl
    Jasmin Bektic
    Karl Dorfinger
    Stephan Hruby
    Klaus Jeschke
    Gero Kramer
    Steffen Krause
    Georg Ludvik
    Mesut Remzi
    Michael Roider
    Franz Stoiber
    Wiener klinische Wochenschrift, 2016, 128 : 156 - 163
  • [29] How should hormone therapy for castration-resistant prostate cancer be continued?
    Spahn, M.
    Krebs, M.
    UROLOGE, 2012, 51 (01): : 15 - +
  • [30] Metastatic castration resistant prostate cancer: Current strategies of management in the Middle East
    Bazarbashi, Should
    Bachour, Marwan
    Bulbul, Muhammad
    Alotaibi, Mohammed
    Jaloudi, Mohamed
    Jaafar, Hassan
    Mukherji, Deborah
    Farah, Nairn
    Alrubai, Tahseen
    Shamseddine, Ali
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2014, 90 (01) : 36 - 48